Compare Boston Scientific Corporation (BSX) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Diamondback Energy Inc — how do they compare? Boston Scientific Corporation trades at $43.2 (market cap $66.37B), while Diamondback Energy Inc trades at $189.76 (market cap $53.64B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Diamondback Energy Inc pays a 2.31% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | FANG | |
|---|---|---|
Market Cap | $66.37B | $53.64B |
Sector | Health | Energy |
52-Week High | $108.14 | $213.69 |
52-Week Low | $42.63 | $134.53 |
Enterprise Value | $75.94B | $67.37B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Diamondback Energy (FANG) trades at $191.6, up 4.48% today, with a bullish technical signal and strong analyst support. The stock shows robust revenue growth, reaching $14.93B in 2025, though net income margins have compressed. Recent earnings beat expectations in Q1 2026, and the company maintains a solid balance sheet with manageable debt levels. A dividend of $1.10 was recently paid, enhancing shareholder returns.
FANG presents a favorable outlook with a consensus price target of $234.50, implying significant upside. However, risks include volatile oil prices, declining profit margins, and execution challenges in a competitive energy sector. The stock's high P/E ratio of 195.51 warrants caution, but strong cash flow and institutional bullishness support a positive investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
